Ion

The Worldwide NGS Kits Industry is Expected to Reach $26 Billion by 2032: Exponential Rise in Next-Generation Sequencing (NGS) Demand due to Reducing Cost of Genome Sequencing - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022

The global NGS kits market is in progressing phase.

Key Points: 
  • The global NGS kits market is in progressing phase.
  • Next-generation sequencing (NGS) has recently seen a rapid surge in popularity and has emerged as a crucial diagnostic tool for many diseases.
  • NGS is a useful technology for characterizing and finding viruses in the environment, animals, and people during viral pandemics.
  • In June 2022, Beckman Coulter, Inc. partnered with Integrated DNA Technologies to distribute Biomek NGenius Next-Generation Sequencing Library Prep System.

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable

Retrieved on: 
Thursday, December 1, 2022

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a subsidiary of OmniAb, Inc. (Nasdaq: OABI) (“OmniAb”) and with Minotaur Therapeutics, Inc. (“Minotaur”) to advance Picobodies against novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.

Key Points: 
  • Targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.
  • Alternative species, particularly camelids and bovines, provide a paradigm for antigen recognition through novel domains which form the antigen binding site.
  • However, for camelids, heavy chain antibodies bind antigen with only a single heavy chain variable region, in the absence of light chains.
  • At ~4-6 kDa, these are three times smaller than a camelid nanobody, and are the smallest known antibody fragment.

Salt Therapy Association Launches Salt Therapy Industry Standards

Retrieved on: 
Tuesday, November 29, 2022

BOCA RATON, Fla., Nov. 29, 2022 /PRNewswire/ -- The Salt Therapy Association (STA) announced the launch of the Salt Therapy Industry Standards(STIS).

Key Points: 
  • BOCA RATON, Fla., Nov. 29, 2022 /PRNewswire/ -- The Salt Therapy Association (STA) announced the launch of the Salt Therapy Industry Standards(STIS).
  • As the world's largest non-profit organization for providers and consumers of salt therapy, STA provides information and resources to create awareness and authentic implementation of salt therapy.
  • Never claim salt therapy is a "cure" for any condition, nor use the word "heal" concerning salt therapy.
  • The association provides ongoing research on the efficacy of dry salt therapy and supports the industry in developing new innovative technologies.

Momentus Signs Contract with Australian Research Centre to Place Satellite in Orbit

Retrieved on: 
Monday, November 28, 2022

(Graphic: CUAVA Training Centre)

Key Points: 
  • (Graphic: CUAVA Training Centre)
    CUAVA is the Australian Research Council Training Centre for CubeSats, Uncrewed Aerial Vehicles, and their Applications.
  • Momentus is proud to partner with CUAVA, a leading Australian research center, said Momentus Chief Executive Officer John Rood.
  • Innovation and pushing the boundaries of technology is what we love to do at Momentus.
  • Momentus is a U.S. commercial space company that offers in-space infrastructure services, including in-space transportation, hosted payloads and in-orbit services.

OSS to Present at the Benchmark Discovery 1x1 Investor Conference, December 1, 2022

Retrieved on: 
Monday, November 21, 2022

ESCONDIDO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in AI Transportable solutions at the edge, has been invited to present at the Benchmark Discovery 1x1 Investor Conference being held at New York Athletic Club in NYC on December 1, 2022.

Key Points: 
  • ESCONDIDO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in AI Transportable solutions at the edge, has been invited to present at the Benchmark Discovery 1x1 Investor Conference being held at New York Athletic Club in NYC on December 1, 2022.
  • OSS president and CEO, David Raun, is scheduled to participate in one-on-one meetings with institutional analysts and investors at the conference.
  • OSS recently reported record Q3 2022 results , with revenue up 18% to a record $18.8 million and non-GAAP EPS of $0.03.
  • To schedule a one-on-one meeting with OSS, you may submit your request online via the link provided upon registration.

4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics

Retrieved on: 
Wednesday, November 16, 2022

4BIO Capital (4BIO) is an international venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future.

Key Points: 
  • 4BIO Capital (4BIO) is an international venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future.
  • Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
  • Based in New York City, Redpin Therapeutics is a privately held, preclinical stage gene therapy company developing a proprietary chemogenetics platform for targeted cell therapies to address currently intractable diseases of the central nervous system.
  • Redpin is building an innovative ion channel-based chemogenetics platform that introduces a new paradigm for tunable, targeted cell therapies.

OSS and TMGcore to Demonstrate World’s First Two-Phase Liquid-Immersion AI Transportable Supercomputer Featuring NVIDIA GPUs for the Edge at SC22

Retrieved on: 
Monday, November 14, 2022

As the worlds first two-phase liquid immersion-cooled supercomputer for AI Transportable applications, this supercomputer represents a new level of operating efficiency, compactness, ruggedness, and performance without compromise.

Key Points: 
  • As the worlds first two-phase liquid immersion-cooled supercomputer for AI Transportable applications, this supercomputer represents a new level of operating efficiency, compactness, ruggedness, and performance without compromise.
  • OSS and TMGcore will demonstrate the new immersion-cooled Rigel Edge Supercomputer at SC22 , the largest international conference for high-performance computing, being held at the Kay Bailey Hutchison Convention Center in Dallas, Texas, on November 14-18.
  • The Rigel Edge Supercomputer will be demonstrated as it operates within TMGcores EdgeBox 4.5 .
  • Bringing these two technologies together demonstrates the potential for a unique, compact, high-performance solution for the transportable edge.

Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio

Retrieved on: 
Wednesday, November 16, 2022

Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.

Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.
  • The acquisition serves as the foundation for Kriyas neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).
  • Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy.
  • The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in metabolic disorders, neurology and ophthalmology.

The Growing Prevalence Of Respiratory Allergies Will Propel The Car Air Purifier Market To More Than $2 Billion By 2026 - By The Business Research Company

Retrieved on: 
Thursday, November 24, 2022

Car air purifiers will be needed to protect people from contaminated outdoor air when traveling in cars.

Key Points: 
  • Car air purifiers will be needed to protect people from contaminated outdoor air when traveling in cars.
  • Thus, the increase in the incidence of respiratory allergies will bolster the demand for car air purifier market.
  • As per the car air purifier market analysis , the introduction of antimicrobial filters is gaining popularity in the car air purifier market.
  • Safety concerns with car air purifiers are expected to be a limiting factor for the growth of the car air purifier market during the forecast period, according to our car air purifier outlook.

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 15, 2022

OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.
  • OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) until its spin-off as an independent publicly traded company as of November 1, 2022.
  • As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here .
  • Net loss for the third quarter of 2022 was $12.6 million, compared with a net loss of $7.9 million for the same period in 2021.